BenzingaAugust 14, 2026 at 6:18 AM NY2 Months Ago
Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
